Pharmaceutical Research Associates Group B.V.

The site conducts extensive studies in Neoplasms, focusing on cancers such as breast and lung that affect a broad patient population. Trials aim to evaluate new therapeutic agents and improve treatment outcomes for advanced disease stages.

• HER2‑negative breast cancer
• Triple‑negative breast cancer
• Advanced non‑small cell lung cancer
• Castration‑resistant prostate cancer
• Follicular lymphoma
• Metastatic breast cancer
• Small cell lung cancer

Pharmaceutical Research Associates Group B.V. leverages its expertise to advance oncology drug development and support patients in Groningen and beyond.

Research at the centre addresses neurodegenerative disorders by testing innovative compounds and diagnostic tools for diseases that impair motor and cognitive function. The goal is to discover treatments that slow progression and improve quality of life.

• Alzheimer’s Disease
• Parkinson’s disease
• Amyotrophic Lateral Sclerosis
• Multiple sclerosis
• Parkinsonian syndromes

Ongoing studies explore disease‑modifying strategies and biomarkers to better understand these conditions.

The programme targets metabolic and cardiovascular diseases, evaluating novel agents that address glucose regulation, weight management, and heart function. Trials are designed to assess safety and therapeutic benefit in at‑risk populations.

• Type 2 Diabetes
• Obesity and overweight
• Chronic heart failure
• Cardiometabolic diseases with inflammatory component
• Cholestatic liver disease
• Chronic kidney disease

Findings support the development of integrated therapies for patients with combined metabolic and cardiac conditions.

Studies focus on infectious and immune‑mediated conditions, aiming to improve treatment options for bacterial infections, parasitic diseases, and rare immune syndromes. Research includes evaluating drug‑drug interactions and novel antimicrobial agents.

• Community‑acquired bacterial pneumonia
• Severe Gram‑negative bacterial infections
• Malaria
• Hereditary angioedema
• Bacterial infection

The site’s work contributes to better therapeutic strategies and resistance management.

The centre addresses rare and genetic diseases by testing targeted therapies and advancing understanding of disease mechanisms. Clinical investigations seek to provide options where few exist.

• Autosomal dominant polycystic kidney disease
• Cryopyrin associated periodic syndrome
• Glycosphingolipid lysosomal storage disorders
• Primary sclerosing cholangitis
• Transthyretin amyloid cardiomyopathy

Collaborative efforts aim to translate genetic insights into effective treatments.

Research includes development of advanced diagnostic and imaging techniques to enhance disease detection and monitoring. Projects evaluate contrast agents, radiolabeled compounds, and pharmacokinetic profiling tools.

• Contrast‑enhanced MRI for head and neck
• PET imaging agents for oncology
• Mass balance studies of radiolabeled drugs
• Pharmacokinetic and bioavailability assessments
• Drug‑drug interaction evaluations

These initiatives support more accurate diagnosis and personalized treatment planning.

The site conducts trials in mental health and psychiatry, focusing on new therapeutics for mood disorders and behavioral conditions. Studies assess efficacy, safety, and impact on daily functioning.

• Major Depressive Disorder
• Behavioral disciplines and activities
• Mental disorders
• Psychiatric assessments

Efforts aim to expand therapeutic options and improve outcomes for patients with psychiatric illnesses.